Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Up 1,230.7% in February

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 389,900 shares, a growth of 1,230.7% from the February 13th total of 29,300 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average trading volume of 336,300 shares, the short-interest ratio is currently 1.2 days.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock opened at $1.38 on Friday. The company has a market capitalization of $19.74 million, a P/E ratio of -1.37 and a beta of 0.54. The company’s 50 day moving average price is $1.88 and its two-hundred day moving average price is $1.74. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55.

Institutional Trading of Chemomab Therapeutics

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Chemomab Therapeutics during the 4th quarter worth approximately $26,000. XTX Topco Ltd raised its holdings in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in Chemomab Therapeutics during the 3rd quarter worth approximately $1,907,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CMMB shares. Oppenheimer reiterated an “outperform” rating and issued a $11.00 price target (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th. Maxim Group increased their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, February 20th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).